Research
China's Aesthetic Medicine Body Contouring Industry
In 2020, the market size of China's aesthetic medicine and body contouring industry was 15.05 billion RMB and will reach 41.78 billion RMB in 2025, with a CAGR of 22.7%. Its main growth momentum arises from people’s changing concept of beauty, as well as increasing acceptance and penetration rate of medical beauty. This report will mainly explore the current market for medical aesthetic body contouring, the key driver for its growth and beauty-seekers' attitude toward this new service.
Learn more
In-depth
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Learn more
Research
WIA2020 | 30 Tech Entrepreneurs in China
This research includes 150 entrepreneurs who operate the most promising technology-based businesses in China. The candidates have been selected based on five distinct categories, including professional background and business achievements. The report is a helpful resource for institutional investors seeking groundbreaking businesses in China, as well as for international corporations that are looking for partnerships in the local market.
Learn more
Latest update：
- 1
China's Aesthetic Medicine Body Contouring Industry
In 2020, the market size of China's aesthetic medicine and body contouring industry was 15.05 billion RMB and will reach 41.78 billion RMB in 2025, with a CAGR of 22.7%. Its main growth momentum arises from people’s changing concept of beauty, as well as increasing acceptance and penetration rate of medical beauty. This report will mainly explore the current market for medical aesthetic body contouring, the key driver for its growth and beauty-seekers' attitude toward this new service.
- 2
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
The investors have a partiality for the projects which could meet clinical needs, possess cutting-edge innovation technology and a talented team.
- 3
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
- 4
WIA2020 | 30 Tech Entrepreneurs in China
This research includes 150 entrepreneurs who operate the most promising technology-based businesses in China. The candidates have been selected based on five distinct categories, including professional background and business achievements. The report is a helpful resource for institutional investors seeking groundbreaking businesses in China, as well as for international corporations that are looking for partnerships in the local market.
Trending
In-depth
Healthcare
Where Will AI Take Drug Discovery in China to?
The development of drug discovery in China is relatively slower than in many other countries but China’s pharma market size is among the top three worldwide. Deeper exploration of drug discovery is much needed in China. AI can make a machine execute tasks like a human or even better than humans. With many emerging AI-powered drug discovery companies in China, can AI help China beat the pioneers in drug discovery at their own game?
Jun 21, 2022 01:19 PM
In-depth
Healthcare
Zai-Lab: Long-Term Bullish
With the bottom line under pressure, Zai-Labs demonstrated growth potential. There is a large unmet demand for novel drugs, particularly in oncology, but competition is fierce. R&D spending accounts for a sizable portion of total spending. However, we anticipate that the pipeline that is currently being developed will help to boost growth.
Jun 17, 2022 02:58 PM
In-depth
Healthcare
Exclusive Interview with Edward Zhou, Managing Partner of Hanne Capital
Jun 15, 2022 01:26 PM
Insight
In-depth
Healthcare
Hui-Gene Therapeutics, China’s Low-Key Game Changer in Gene Therapy
Jun 06, 2022 12:37 PM
Research Reports
More
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Aug 09, 2020 12:23 AM
Research
Healthcare, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
News More
Team
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.